Analysis

A new report examines seven drugs "for which there was no new clinical evidence that could support their price increases."

How much can Medicare pricing data and working with carriers to narrow networks bring down health costs for employers?

In a recent survey, 82 percent of those with a diagnosed mental health condition said they didn't tell bosses.

Here's what advisors and sponsors need to know about the 3 cases involving Intel, IBM, and U.S. Bank.

Removing cost barriers to life-saving prescription drugs does encourage adherence--but not for everyone.

Finding innovative ways to get a handle on pharmaceutical spending is a top priority for employers.